ReNeuron to advance stem cell-based stroke therapy trial
This article was originally published in Clinica
Executive Summary
ReNeuron has got the go-ahead to expand its PISCES UK Phase I study of its ReN001 foetal-derived stem cell therapy for ischaemic stroke. The trial can now enrol a second cohort of patients who will be treated with a higher dose of ReN001. The first cohort of three patients, who received the lowest dose of therapy, has now been assessed, and no adverse events have been reported.